Helicobacter pylori infection and diabetes mellitus: The 2013 state of art

Panminerva Medica

Volumn 55, Issue 3, 2013, Pages 277-281

  Marietti, M ^a   Gasbarrini, A ^b   Saracco, G ^c   Pellicano, R ^a  

^a SCDU Gastro Hepatology   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Diabetes mellitus; Helicobacter pylori; Therapeutics.

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DIABETES MELLITUS; DYSPEPSIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DIABETES MELLITUS; DRUG RESISTANCE, BACTERIAL; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INSULIN RESISTANCE; PREVALENCE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84891812269     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. El-Eshmawy MM, El-Hawary AK, Abdel Gawad SS, El-Baiomy AA. Helicobacter pylori infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. Diabetol Metab Syndr 2011;3:28.
2. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
3. Malfertheiner P, Megraud F, O'Morain C, Atherton J, Axon AT, Bazzoli F et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
4. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter 2009; 14(Suppl. 1) :58-68.
5. Vizzardi E, Bonadei I, Piovanelli B, Quinzani F, Ricci C, Lanzini A et al. Helicobacter pylori and ischemic heart disease. Panminerva Med 2011;53:193-202.
6. Arslan D, Kendirci M, Kurtoglu S, Kula M. Helicobacter pylori infection in children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 2000;13:553-6. (Pubitemid 30253148)
7. Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus. A meta-analysis of observational studies. Diabetes Res Clin Pract 2013;99:200-8.
8. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: Is there a link? World J Gastroenterol 2009;15:2701-7.
9. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011; 16:79-88.
10. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009;14:144-50.
11. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009;54:1966-70.
12. Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries 2010;30:22-6.
13. Oh JH, Choi MG, Kang MI, Lee KM, Kim JI, Kim BW et al. The prevalence of gastrointestinal symptoms in patients with non-insulin dependent diabetes mellitus. Korean J Intern Med 2009:24:30917.
14. Jarmuzewska EA, Mangoni AA. Electrophysiological and clinical study of type-2 diabetic patients with short duration of disease and normal generalized nerve conductions. Panminerva Med 2011;53:111.
15. Sfarti C, Trifan A, Hutanasu C, Cojocariu C, Singeap AM, Stanciu C. Prevalence of gastroparesis in type 1 diabetes mellitus and its relationship to dyspeptic symptoms. J Gastrointestin Liver Dis 2010;19:279-84.
16. Quatrini M, Boarino V, Ghidoni A, Baldassarri AR, Bianchi PA, Bardella MT. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol 2001;32:215-7. (Pubitemid 32174111)
17. Rahman MA, Cope MB, Sarker SA, Garvey WT, Chaudhury HS, Khaled MA. Helicobacter pylori infection and inflammation: implication for the pathophysiology of diabetes and coronary heart disease in Asian Indians. J. Life Sci 2009;1:45-50.
18. Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005;28:214-7 (Pubitemid 43162767)
19. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci 2008;53:2646-9.
20. Koskenpato J, Korppi-Tommola T, Kairemo K, Färkkilä M. Longterm follow-up study of gastric emptying and Helicobacter pylori eradication among patients with functional dyspepsia. Dig Dis Sci 2000;45:1763-8.
21. 13C-octanoic acid breath test and the acctaminophen method. J Gastroenterol Hepatol 2006;21:824-30.
22. Diomedi M, Stanzione P, Sallustio F, Leone G, Renna A, Misaggi G et al. Cytotoxin-associated gene-A-positive Helicobacter pylori strains infection increases the risk of recurrent atherosclerotic stroke. Helicobacter 2008;13:525-31.
23. Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA et al. Vascular risks and complications in diabetes mellitus: the role of Helicobacter pylori infection. J Stroke Cerebrovasc Dis 2008;17:86-94. (Pubitemid 351381447)
24. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012;35:520-5.
25. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9. (Pubitemid 40629025)
26. Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010; 15(Suppl. 1) : 14-20.
27. Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity and vaccines for Helicobacter. Helicobacter 2010; 15(Suppl. 1):21-8.
28. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010;31:817-44.
29. Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR et al. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol 2011;11:37.
30. Roper J, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ et al. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J Clin Endocrinol Metab 2008;93:2350-7. (Pubitemid 351831558)
31. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol 2011;45:50-4.
32. Arslan E, Atilgan H, Yavaçoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med 2009;20:695-7.
33. Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 2009;44:104654.
34. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15(Suppl. 1):60-8.
35. So WY, Tong PC, Ko GT, Ma RC, Ozaki R, Kong AP et al. Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. Diabetes Res Clin Pract 2009;86:89-95.
36. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, Gasbarrini A. Helicobacter pylori infection and diabetes. Minerva Med 2010;101:115-9.
37. Pietroiusti A, Giuliano M, Magrini A, Bergamaschi A, Galante A. Cytotoxin-associated gene A strains of Helicobacter pylori represent a risk factor for the development of microalbuminuria in type 2 diabetes. Diabetes Care 2006;29:1399-401. (Pubitemid 44125946)
38. Colturi TJ, Unger RH, Feldman M. Role of circulating somatostatin in regulation of gastric acid secretion, gastrin release, and islet cell function. Studies in healthy subjects and duodenal cell patients. J Clin Invest 1984;74:417-23. (Pubitemid 14053988)
39. Peach HG, Barnett NE. Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Pathol 2001;54:466-9. (Pubitemid 32531097)
40. Fagoonee S, Pellicano R. Ampicillin-based therapy for Helicobacter pylori eradication. Panminerva Med 2011;53:261.
41. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III Consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
42. Cisarô F, Astegiano M, De Angelis C, Saracco G, Rizzetto M, Pellicano R. Ranitidine bismuth citrate in the first-line of helicobacter pylori treatment. Panminerva Med 2011;53:138.
43. Güzelbulut F, Sezikli M, Akkan Çetinkaya Z, Erhan Altunöz M, Günes P, Düzgün S et al. Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice? Minerva Med 2011; 102:171-6.
44. Me'graud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:3442.
45. Ojetti V, Pitocco D, Ghirlanda G, Gasbarrini G, Gasbarrini A. Role of Helicobacter pylori infection in insulin-dependent diabetes mellitus. Minerva Med 2001;92:137-44. (Pubitemid 32708888)
46. Gasbarrini A, Ojetti V, Pitocco D, Franceschi F, Candelli M, Torre ES et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:713-6. (Pubitemid 29349012)
47. Gasbarrini A, Ojetti V, Pitocco D, Armuzzi A, Silveri NG, Pola P et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260-3. (Pubitemid 30217177)
48. Candelli M, Rigante D, Marietti G, Nista EC, Crea F, Schiavino A et al. Helicobacter pylori eradication rate and glycémie control in young patients with type 1 diabetes. J Pediatr Gastroenterol Nutr 2004;38:422-5.
49. Sargyn M, Uygur-Bayramicli O, Sargyn H, Orbay E, Yavuzer D, Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003;9:1126-8. (Pubitemid 36681694)
50. Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009; 102:1116-20.
51. Schamagl H, Kist M, Grawitz AB, Koeing W, Wieland H, März W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. Am J Cardiol 2004;93:219-20. (Pubitemid 38058736)
52. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010;103:190-6.
53. 2 values. Aliment Pharmacol Ther 2006;23:275-80.
54. Candelli M, Rigante D, Schiavino A, Gabrielli M, Crea F, Minguell Del Lungo L et al. High reinfection rate of Helicobacter pylori in young type 1 diabetic patients: a three-year follow-up study. Eur Rev Med Pharmacol Sci 2012;16:1468-72.
55. Ojetti V, Pitocco D, Bartolozzi F, Danese S, Migneco A, Lupascu A et al. High rate of Helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care 2002;25:1485.
56. Ojetti V, Migneco A, Nista EC, Gasbarrini G, Gasbarrini A, Pitocco D et al. H.pylori re-infection in type 1 diabetes: a 5 years follow-up. Dig Liver Dis 2007;39:286-7. (Pubitemid 46196440)